Featured Research

from universities, journals, and other organizations

Women at higher risk than men of kidney damage after heart imaging test

Date:
April 27, 2011
Source:
Henry Ford Health System
Summary:
Women are at higher risk than men of developing kidney damage after undergoing a coronary angiogram, according to a new study. Researchers found that women are 60 percent more likely than men to develop radiocontrast-induced nephropathy, an adverse side effect that causes kidney dysfunction within 24 to 72 hours after patients are administered an iodine contrast dye during the common heart imaging test.

Women are at higher risk than men of developing kidney damage after undergoing a coronary angiogram, according to a Henry Ford Hospital study.

Researchers found that women are 60 percent more likely than men to develop radiocontrast-induced nephropathy (RCIN), an adverse side effect that causes kidney dysfunction within 24 to 72 hours after patients are administered an iodine contrast dye during the common heart imaging test.

This is believed to be the first study in which researchers investigated whether gender played a role in patients developing RCIN after undergoing a coronary angiogram. RCIN is the third-leading cause of hospital-acquired kidney damage in the United States, after surgery and hypertension.

The study was presented April 27 at the National Kidney Foundation's Spring Clinical Meeting in Las Vegas.

While researchers say further study is needed to explain the gender risk, they theorize that a woman's size may be a factor, says Javier Neyra, M.D., an Internal Medicine resident at Henry Ford and the study's principal investigator.

"Because men and women patients receive the same amount of dye during a coronary angiogram, it's possible the amount is just too much for a woman's body to handle given her smaller size," Dr. Neyra says. "Perhaps a woman's height and weight ought to be factored into the dosage."

Dr. Neyra says the contrast dye may cause the kidney's blood vessels to narrow, thus causing damage to the organ. He says women with a history of heart disease should consult with their physician about undergoing heart imaging tests using contrast dyes.

Contrast dye is used to improve the visibility of internal body structures during an imaging test. In a coronary angiogram, the dye enhances images of the heart's blood vessels and chambers.

In the Henry Ford study, researchers followed 1,211 patients who received a coronary angiogram from January 2008 to December 2009. Nearly 20 percent of women developed RCIN compared to 13.6 percent of men.

Dr. Neyra says other contributing factors in the gender risk could be age, hormonal levels and other chronic conditions. "We just don't know without further study," he says.

The study was funded by Henry Ford Hospital.


Story Source:

The above story is based on materials provided by Henry Ford Health System. Note: Materials may be edited for content and length.


Cite This Page:

Henry Ford Health System. "Women at higher risk than men of kidney damage after heart imaging test." ScienceDaily. ScienceDaily, 27 April 2011. <www.sciencedaily.com/releases/2011/04/110427231659.htm>.
Henry Ford Health System. (2011, April 27). Women at higher risk than men of kidney damage after heart imaging test. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2011/04/110427231659.htm
Henry Ford Health System. "Women at higher risk than men of kidney damage after heart imaging test." ScienceDaily. www.sciencedaily.com/releases/2011/04/110427231659.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins